Skip to content

Is Capricor Therapeutics (CAPR) worth the risk?

What’s up with Capricor Therapeutics?

Capricor Therapeutics (CAPR) opened at $6.85, which means the stock is up 5.87% from yesterday’s closing price of 7.00. Today, the company has a high of $9.10 and a low of $6.52. The company has a market cap of $90.61 million with a 52-week high of $11.08 and a 52-week low of $0.88.

Advertisements

What about the future for Capricor Therapeutics

The high forecast for Capricor Therapeutics is 9.00 while the low is 4.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Capricor Therapeutics has a weak forecast. A weak forecast is due to the company posting consistent losses in their earning reports. The future outlook does not seem too bright as this could potentially cause the company to file for bankruptcy.. Based on this information CAPR seems to be a risky buy.

About Capricor Therapeutics
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

Leave a Reply

%d bloggers like this: